RCM Eos Holdings

RCM Eos Holdings LLC is a healthcare-focused investment vehicle managed by Rapha Capital Management, LLC, a venture capital firm founded by Dr. Kevin Slawin. The entity was established to facilitate the financing and strategic development of Eos SENOLYTIX, a biotechnology company specializing in gerotherapeutics and mitochondrial-targeted therapies. In March 2026, RCM Eos Holdings provided bridge financing as part of a $19 million transaction involving the merger of Eos SENOLYTIX with Pulmatrix, Inc. (Nasdaq: PULM). Through its primary interest in Eos SENOLYTIX, the company advances the MitoXcel™ platform, which utilizes AI-driven peptide design to address mitochondrial dysfunction and senescent cells in age-related diseases. The company's lead clinical candidate, PTC-2105, is currently being evaluated for the treatment of sarcopenia and sarcopenic obesity. RCM Eos Holdings plays a pivotal role in the commercialization of these novel geropeptides, which aim to improve healthspan by rejuvenating mitochondrial efficiency.